Regulatory News

• Undark-STAT Investigation Reveals Hidden History of BPC-157

  A Pulitzer Center-backed investigation traces Predrag Sikiric's 50-year quest behind BPC-157, questioning its evidence base ahead of July's FDA review.

  May 31, 2026

• Leana Wen Warns Wellness Peptide Craze Sidesteps Clinical Trials

  Leana Wen warns wellness peptides replace clinical trials with self-experimentation, as med spas market unapproved compounds without safety details.

  May 28, 2026

• RFK Jr. Forces FDA Peptide Review as Young Men Inject at Epidemic Rate

  RFK Jr. pushes FDA to reverse its 2023 peptide ban as a USA Today opinion piece documents young men injecting unregulated peptides at dangerous levels.

  May 25, 2026

• 45% of Social-Media Peptide Buyers Visited the ER, New Survey Finds

  A Sunlight survey of 1,000 U.S. peptide users finds social-media buyers are 3x more likely to land in the ER, while 75% used AI for dosing guidance.

  May 24, 2026

• ECRI, ISMP Warn Wellness Peptide Market Outpaced Clinical Evidence

  Joint white paper finds 35 of 36 BPC-157 studies were animal-only, gray-market purity as low as 5%, and heavy metal contamination in injectable products.

  May 17, 2026

• Lancet Warns Peptide Craze Outpacing Regulation — BPC-157, Retatrutide

  The Lancet warns social-media peptide use among youth is outpacing regulators, citing BPC-157, CJC-1295, and Retatrutide as primary concerns.

  May 11, 2026

• Australia’s TGA Warns on Illegal Peptides as Global Crackdown Widens

  Australia’s TGA warns on illegal peptide use and border seizures as global regulators escalate enforcement ahead of July’s FDA PCAC meeting on seven compounds.

  May 10, 2026

• Week Ahead: Global Peptide Warnings, GLP-1 Comment Prep, PCAC Watch

  Australia’s TGA peptide warning sets international tone, GLP-1 503B comment prep begins, and PCAC briefing materials for July remain anticipated.

  May 10, 2026

• FDA Compounding Pharmacy Enforcement Intensifies Ahead of July PCAC

  Compounding pharmacy enforcement is intensifying with FDA warning letters and a GLP-1 503B exclusion proposal ahead of the July PCAC peptide meeting.

  May 6, 2026

• Melanotan II Tanning Trend Draws Scrutiny Ahead of July PCAC Review

  WWD covers the Melanotan II tanning trend ahead of July PCAC review, highlighting the regulatory stakes for a peptide at the center of beauty and FDA policy.

  May 5, 2026

• FDA Semaglutide Decision Signals Tougher Peptide Compounding Standard

  The FDA's April 30 proposal to end large-scale GLP-1 compounding uses the same clinical-need standard that will govern peptide compounding after PCAC.

  May 4, 2026

• FDA Proposes Excluding GLP-1 Drugs From 503B Compounding List

  Test description.

  May 3, 2026

• FDA Sets July PCAC Meeting to Review Seven Peptide Therapies

  The FDA has scheduled a July 2026 PCAC meeting to review seven peptide therapies including BPC-157, marking a potential shift in regulatory approach.

  May 1, 2026

• Why the Research-Chemical Gray Market Is Not Going Away (And What to Do About It)

  The April 15 reclassification cleared the prescription path for peptides. It did nothing to address the research-chemical channel — which is more dangerous now.

  Apr 26, 2026

• What the July 23–24 PCAC Meeting Will Actually Decide

  The July PCAC meeting will determine final 503A Bulks List placement for the twelve reclassified peptides. The three possible outcomes and what each means.

  Apr 25, 2026

• FDA Removes 12 Therapeutic Peptides From Category 2 — What the April 15 Action Means

  The FDA's April 15 reclassification opens a legal compounding path for BPC-157, TB-500, and 10 other peptides. What it does — and doesn't — change.

  Apr 23, 2026